{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:33:11Z","timestamp":1765888391654,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40266-020-00790-x","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T01:02:20Z","timestamp":1597021340000},"page":"715-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Optimizing the Treatment of Moderate-to-Severe Psoriasis in Older Adults"],"prefix":"10.1007","volume":"37","author":[{"given":"Nico","family":"Shary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5160-2130","authenticated-orcid":false,"given":"Robert E.","family":"Kalb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"issue":"6","key":"790_CR1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"120","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;120(6):1475.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"790_CR2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"790_CR3","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/ket363","volume":"53","author":"R Queiro","year":"2014","unstructured":"Queiro R, Tej\u00f3n P, Alonso S, et al. Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology. 2014;53(7):1178\u201385.","journal-title":"Rheumatology"},{"issue":"3","key":"790_CR4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","volume":"60","author":"M Icen","year":"2009","unstructured":"Icen M, Crowson CS, McEvoy MT, et al. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394\u2013401.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"790_CR5","first-page":"228","volume":"38","author":"MH Noe","year":"2018","unstructured":"Noe MH, Shin DB, Wan MT, et al. Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study. J Investig Dermatol. 2018;38(1):228\u201330.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"790_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2340\/00015555-1193","volume":"92","author":"E Hrehor\u00f3w","year":"2012","unstructured":"Hrehor\u00f3w E, Salomon J, Matusiak L, et al. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012;92(1):67\u201372.","journal-title":"Acta Derm Venereol"},{"issue":"20","key":"790_CR7","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.162.20.2269","volume":"162","author":"JL Wolff","year":"2002","unstructured":"Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern. 2002;162(20):2269\u201376.","journal-title":"Arch Intern"},{"issue":"2","key":"790_CR8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.berh.2018.09.006","volume":"32","author":"D Solmaz","year":"2018","unstructured":"Solmaz D, Eder L, Aydin SZ. Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):295\u2013311.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"790_CR9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","volume":"24","author":"E Christophers","year":"2010","unstructured":"Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548\u201354.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"790_CR10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/joim.12002","volume":"273","author":"KH Yiu","year":"2013","unstructured":"Yiu KH, Yeung CK, Zhao CT, et al. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med. 2013;273(3):273\u201382.","journal-title":"J Intern Med"},{"issue":"8","key":"790_CR11","doi-asserted-by":"crossref","first-page":"775.e1","DOI":"10.1016\/j.amjmed.2011.03.028","volume":"124","author":"NN Mehta","year":"2011","unstructured":"Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1\u20137756.","journal-title":"Am J Med"},{"issue":"2","key":"790_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jcdd6020019","volume":"6","author":"JL Rodgers","year":"2019","unstructured":"Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019;6(2):19.","journal-title":"J Cardiovasc Dev Dis."},{"issue":"3","key":"790_CR13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","volume":"70","author":"EA van der Voort","year":"2014","unstructured":"van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55\u00a0years old or older: results from a population-based study. J Am Acad Dermatol. 2014;70(3):517\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"790_CR14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1023\/A:1005446418589","volume":"45","author":"Y Tsushima","year":"2000","unstructured":"Tsushima Y, Endo K. Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci. 2000;45(1):196\u2013200.","journal-title":"Dig Dis Sci"},{"issue":"22","key":"790_CR15","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.3748\/wjg.v21.i22.6892","volume":"21","author":"N Balato","year":"2015","unstructured":"Balato N, Napolitano M, Ayala F, Patruno C, Megna M, Tarantino G. Nonalcoholic fatty liver disease, spleen and psoriasis: new aspects of low-grade chronic inflammation. World J Gastroenterol. 2015;21(22):6892\u20137.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"790_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13555-016-0153-2","volume":"7","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97\u2013109.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"790_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"key":"790_CR18","first-page":"3446","volume":"2007","author":"D Ihtatho","year":"2007","unstructured":"Ihtatho D, Fadzil MH, Affandi AM, Hussein SH. Area assessment of psoriasis lesion for PASI scoring. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:3446\u20139.","journal-title":"Conf Proc IEEE Eng Med Biol Soc."},{"issue":"6","key":"790_CR19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","volume":"28","author":"BE Elewski","year":"2017","unstructured":"Elewski BE, Puig L, Mordin M, et al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatol Treat. 2017;28(6):492\u20139.","journal-title":"J Dermatol Treat."},{"issue":"8","key":"790_CR20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40266-017-0480-8","volume":"34","author":"JG Kamel","year":"2017","unstructured":"Kamel JG, Yamauchi PS. Managing mild-to-moderate psoriasis in elderly patients: role of topical treatments. Drugs Aging. 2017;34(8):583\u20138.","journal-title":"Drugs Aging"},{"issue":"4","key":"790_CR21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2010.08.011","volume":"126","author":"PJ Busse","year":"2010","unstructured":"Busse PJ, Mathur SK. Age-related changes in immune function: effect on airway inflammation. J Allergy Clin Immunol. 2010;126(4):690\u2013701.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"790_CR22","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","volume":"7","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567.","journal-title":"BMJ Open"},{"issue":"1","key":"790_CR23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","volume":"77","author":"I Snast","year":"2017","unstructured":"Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88\u201397.","journal-title":"J Am Acad Dermatol"},{"key":"790_CR24","unstructured":"Chiu HY, Chiu YM, Chang Liao NF, et al. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agent: a nine-year multicenter cohort study. J Am Acad Dermatol. 2019."},{"issue":"5","key":"790_CR25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/014107688307600514","volume":"76","author":"K Kafetz","year":"1983","unstructured":"Kafetz K. Renal impairment in the elderly: a review. J R Soc Med. 1983;76(5):398\u2013401.","journal-title":"J R Soc Med"},{"issue":"1","key":"790_CR26","first-page":"38","volume":"22","author":"JM Kremer","year":"1995","unstructured":"Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6\u00a0months of therapy. J Rheumatol. 1995;22(1):38\u201340.","journal-title":"J Rheumatol"},{"issue":"5","key":"790_CR27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2008;58(5):826\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"790_CR28","first-page":"CD007893","volume":"1","author":"N Robert","year":"2010","unstructured":"Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;1:CD007893.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"790_CR29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/acr.22294","volume":"66","author":"G Schmajuk","year":"2014","unstructured":"Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res (Hoboken). 2014;66(8):1159\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"790_CR30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000275198","volume":"220","author":"JH Saurat","year":"2010","unstructured":"Saurat JH, Gu\u00e9rin A, Yu AP, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology. 2010;220(2):128\u201337.","journal-title":"Dermatology"},{"issue":"1","key":"790_CR31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.14336\/AD.2017.0306","volume":"9","author":"S Wongrakpanich","year":"2018","unstructured":"Wongrakpanich S, Wongrakpanich A, Melhado K, et al. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143\u201350.","journal-title":"Aging Dis."},{"issue":"4","key":"790_CR32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2020.1728253","volume":"19","author":"R Di Caprio","year":"2020","unstructured":"Di Caprio R, Caiazzo G, Cacciapuoti S, et al. Safety concerns with current treatments for psoriasis in the elderly. Expert Opin Drug Saf. 2020;19(4):523\u201331.","journal-title":"Expert Opin Drug Saf."},{"issue":"10","key":"790_CR33","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.2105\/AJPH.94.10.1788","volume":"94","author":"AL Fitzpatrick","year":"2004","unstructured":"Fitzpatrick AL, Powe NR, Cooper LS, et al. Barriers to health care access among the elderly and who perceives them. Am J Public Health. 2004;94(10):1788\u201394.","journal-title":"Am J Public Health"},{"issue":"4","key":"790_CR34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaad.2018.03.018","volume":"79","author":"SY Tan","year":"2018","unstructured":"Tan SY, Buzney E, Mostaghimi A. Trends in phototherapy utilization among Medicare beneficiaries in the United States, 2000 to 2015. J Am Acad Dermatol. 2018;79(4):672\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3\u20134","key":"790_CR35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1475-5890.2016.12106","volume":"37","author":"M De Nardi","year":"2016","unstructured":"De Nardi M, French E, Jones JB, et al. Medical spending of the US elderly. Fisc Stud. 2016;37(3\u20134):717\u201347.","journal-title":"Fisc Stud."},{"issue":"1","key":"790_CR36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40257-019-00468-0","volume":"21","author":"NE Natsis","year":"2020","unstructured":"Natsis NE, Merola JF, Weinberg JM, et al. Treatment of Medicare patients with moderate-to-severe psoriasis who cannot afford biologics or apremilast. Am J Clin Dermatol. 2020;21(1):109\u201317.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"790_CR37","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1038\/jid.2015.296","volume":"135","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Investig Dermatol. 2015;135(12):2955\u201363.","journal-title":"J Investig Dermatol."},{"issue":"Suppl 2","key":"790_CR38","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.2310\/7750.2009.00023","volume":"13","author":"R Bissonnette","year":"2009","unstructured":"Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. J Cutan Med Surg. 2009;13(Suppl 2):S67\u201376.","journal-title":"J Cutan Med Surg."},{"issue":"3","key":"790_CR39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2340\/00015555-1719","volume":"94","author":"S Piaserico","year":"2014","unstructured":"Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"790_CR40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","volume":"155","author":"ED Dommasch","year":"2019","unstructured":"Dommasch ED, Kim SC, Lee MP, et al. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019;155(10):1142\u201352.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"790_CR41","first-page":"587","volume":"151","author":"M Napolitano","year":"2016","unstructured":"Napolitano M, Balato N, Ayala F, et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. G Ital Dermatol Venereol. 2016;151(6):587\u201395.","journal-title":"G Ital Dermatol Venereol."},{"issue":"4","key":"790_CR42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000345623","volume":"225","author":"M Esposito","year":"2012","unstructured":"Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225(4):312\u20139.","journal-title":"Dermatology"},{"issue":"3","key":"790_CR43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","volume":"63","author":"A Menter","year":"2010","unstructured":"Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"790_CR44","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1080\/14740338.2016.1226279","volume":"15","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A, Pavlidis A, Dattola A, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. Expert Opin Drug Saf. 2016;15(11):1459\u201362.","journal-title":"Expert Opin Drug Saf."},{"issue":"11","key":"790_CR45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","volume":"20","author":"SM Schumacher","year":"2018","unstructured":"Schumacher SM, Naga Prasad SV. Tumor necrosis factor-\u03b1 in heart failure: an updated review. Curr Cardiol Rep. 2018;20(11):117.","journal-title":"Curr Cardiol Rep."},{"key":"790_CR46","doi-asserted-by":"publisher","first-page":"212570","DOI":"10.7573\/dic.212570","volume":"8","author":"AC Foulkes","year":"2019","unstructured":"Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570. https:\/\/doi.org\/10.7573\/dic.212570.","journal-title":"Drugs Context."},{"issue":"2","key":"790_CR47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","volume":"35","author":"A K\u00f6rber","year":"2018","unstructured":"K\u00f6rber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135\u201344.","journal-title":"Drugs Aging"},{"key":"790_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14258","author":"M Megna","year":"2020","unstructured":"Megna M, Camela E, Cinelli E, et al. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2020. https:\/\/doi.org\/10.1111\/ced.14258.","journal-title":"Clin Exp Dermatol."},{"issue":"3","key":"790_CR49","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/jdv.16063","volume":"34","author":"M Megna","year":"2020","unstructured":"Megna M, Cinelli E, Balato A, et al. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. J Eur Acad Dermatol Venereol. 2020;34(3):e152\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"790_CR50","first-page":"AB176","volume":"81","author":"M Lebwohl","year":"2019","unstructured":"Lebwohl M, Yamauchi P, Wu JJ, et al. Brodalumab in patients with psoriasis ages < 65 and 65 years: 120-week findings from two phase 3 studies. J Am Acad Dermatol. 2019;81(4):AB176.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"790_CR51","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ced.12850","volume":"41","author":"M Megna","year":"2016","unstructured":"Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41(5):564\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"790_CR52","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","volume":"41","author":"M Hayashi","year":"2014","unstructured":"Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974\u201380.","journal-title":"J Dermatol"},{"issue":"9","key":"790_CR53","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jdv.15653","volume":"33","author":"JJ Crowley","year":"2019","unstructured":"Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"790_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/idoj.IDOJ_437_18","volume":"10","author":"TP Afra","year":"2019","unstructured":"Afra TP, Razmi TM, Dogra S. Apremilast in psoriasis and beyond: big hopes on a small molecule. Indian Dermatol Online J. 2019;10(1):1\u201312.","journal-title":"Indian Dermatol Online J."},{"key":"790_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16443","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Camela E, et al. Apremilast efficacy and safety in elderly psoriasis patients over a 48-weeks. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16443.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"790_CR56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10103-017-2360-1","volume":"33","author":"P Zhang","year":"2018","unstructured":"Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2018;33(1):173\u201380.","journal-title":"Lasers Med Sci"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-020-00790-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T09:35:15Z","timestamp":1667727315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-020-00790-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00790-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"10 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author(s) declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}